Progenity Announces Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology

Rhea-AI Summary

Progenity (Nasdaq: PROG) announced that Dr. Bram Verstockt will present patient data demonstrating a correlation between drug levels and clinical outcomes at the 34th Belgian Week of Gastroenterology, scheduled for February 9-11, 2022. The presentation will focus on the endoscopic outcomes in patients treated with tofacitinib, correlating these results with tissue exposure to the drug. This acceptance marks a significant opportunity for Progenity to highlight the efficacy of its oral biotherapeutics for gastrointestinal health.

Positive

• Dr. Bram Verstockt's presentation accepted at a prominent gastroenterology event highlights the company's research credibility.
• The presentation will address clinical outcomes related to tofacitinib, showcasing the potential efficacy of Progenity's drug.

Negative

• None.

Dr. Bram Verstockt to present patient data establishing correlation between drug levels in colon and clinical outcomes

SAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that patient data on indicators of efficacy in the treatment of gastrointestinal disorders has been accepted for oral presentation during the 34^th edition of the Belgian Week of Gastroenterology, February 9-11, 2022.

Details of the presentations are as follows:

	Presentation Title:	Endoscopic outcome in tofacitinib treated patients correlated with tofacitinib tissue exposure
	Presenter Name:	Bram Verstockt, MD, PhD
	Session Date & Time:	February 9, 2022, 9:24 to 9:34 CET

The abstract is now available on the BWGE 2022 website.

About Progenity

Progenity, Inc. is a biotechnology company innovating in the fields of women’s health, gastrointestinal health and oral biotherapeutics. Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.

For more information visit www.progenity.com, or follow the company on LinkedIn or Twitter.

Investor Contact:
Robert Uhl
Managing Director, ICR Westwicke
ir@progenity.com
(619) 228-5886

Media Contact:
Kristin Schaeffer
CG Life
media@progenity.com
858-457-2436

FAQ

What is the focus of Dr. Bram Verstockt's presentation at the Belgian Week of Gastroenterology?

Dr. Bram Verstockt will present data correlating drug levels of tofacitinib with clinical outcomes in treated patients.

When will Progenity's presentation take place during the Belgian Week of Gastroenterology?

The presentation is scheduled for February 9, 2022, from 9:24 to 9:34 CET.

What is Progenity's stock symbol?

Progenity's stock symbol is PROG.

What therapeutic area does Progenity focus on?

Progenity specializes in oral biotherapeutics, particularly for gastrointestinal health.

Where can I find more information about Progenity?

More information can be found on Progenity's official website at www.progenity.com.